SCHEMBL13035686

SCHEMBL13035686

COc1ccc(C2Nc3cccc4cccc(c34)N2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 18/20 1.00
KMT2A Q03164 18/20 1.00
GAA P10253 9/20 1.00
MAPT P10636 5/20 1.00
KDM4E B2RXH2 4/20 1.00
ALDH1A1 P00352 4/20 1.00
NPC1 O15118 6/20 0.71
AR P10275 3/20 0.65
IDE P14735 1/20 0.65
L3MBTL1 Q9Y468 2/20 0.64
MAPK1 P28482 1/20 0.64
HSP90AA1 P07900 1/20 0.64
RAB9A P51151 1/20 0.64
USP2 O75604 1/20 0.61
POLB P06746 1/20 0.61
HPGD P15428 1/20 0.61
ESR2 Q92731 1/20 0.61
HSD17B10 Q99714 1/20 0.61
TNKS2 Q9H2K2 1/20 0.60
ALOX12 P18054 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13035675 0.87 MEN1 (0.84) MEN1KMT2AGAAMAPTKDM4E
SCHEMBL21891264 0.85 MEN1 (0.74) MEN1KMT2AGAAMAPTKDM4E
SCHEMBL13035685 0.82 MEN1 (1.00) MEN1KMT2AGAAMAPTKDM4E
SCHEMBL13035703 0.82 MEN1 (1.00) MEN1KMT2AGAAMAPTKDM4E
SCHEMBL13035699 0.80 MEN1 (1.00) MEN1KMT2AGAAMAPTKDM4E
SCHEMBL13035695 0.79 MEN1 (1.00) MEN1KMT2AGAAMAPTKDM4E
SCHEMBL4160714 0.79 MEN1 (0.70) MEN1KMT2AGAAMAPTKDM4E
SCHEMBL11568615 0.79 MEN1 (1.00) MEN1KMT2AGAAMAPTKDM4E
SCHEMBL11569089 0.79 MEN1 (0.70) MEN1KMT2AGAAMAPTKDM4E
SCHEMBL13035694 0.79 MEN1 (1.00) MEN1KMT2AGAAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297046-A1 Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors DYNAMIS THERAPEUTICS, INC. (US) 2010-11-25 US disclosed
US-20100297046-A1 Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors DYNAMIS THERAPEUTICS, INC. (US) 2010-11-25 US disclosed
WO-2007117394-A2 COMPOSITIONS AND METHODS RELATED TO FRUCTOSAMINE-3-KINASE INHIBITORS DYNAMIS THERAPEUTICS, INC. (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297046-A1 Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors FN3K, ROS1, FN3KRP MEN1 4765/4885KMT2A 2677/4885GAA 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.